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Upon recognition of microbial products, Toll-like receptors (TLRs) recruit distinct combina-
tions of adaptors to induce TLR-specific gene expression. In this issue, Kagan and Medzhitov 
(2006) demonstrate that the adaptor TIRAP/Mal localizes to the plasma membrane by 
binding to phosphatidylinositol 4,5-bisphosphate (PIP2). This binding recruits a key adaptor 
MyD88 to TLR4, suggesting that there is crosstalk between the TLR signaling pathway and 
phospholipid metabolism.Toll-like receptors (TLRs) recognize 
microbial products and initiate a 
complex immune response designed 
to eliminate invading pathogens. 
A key structural motif involved in 
the signal transduction of TLRs is 
the Toll/IL-1 receptor (TIR) domain 
(reviewed in Dunne and O’Neill, 
2003). TIR domains can be found in 
the cytoplasmic portions of all TLRs, 
the IL-1 receptor family, and a group 
of adaptor proteins. This latter group 
includes myeloid differentiation fac-
tor 88 (MyD88); TIR-domain-con-
taining adaptor protein (TIRAP), also 
called MyD88 adaptor-like (Mal); TIR-
domain-containing adaptor induc-
ing interferon-β (TRIF), also called 
TICAM-1; and TRIF-related adap-
tor molecule (TRAM), or TICAM-2. 
Although nearly all TLRs recruit 
MyD88, only some recruit TIRAP, 
TRIF, and TRAM, giving rise to speci-
ficity in signaling. In this issue, Kagan 
and Medzhitov (2006) provide fresh 
insights into how TIRAP and MyD88 
are recruited to TLR4 in the plasma 
membrane.
MyD88 activates the serine/threo-
nine IRAK kinases IRAK1 and IRAK4. 
The IRAKs then enable the recruit-
ment and activation of tumor necro-
sis factor receptor-associated factor 
6 (TRAF-6), a RING-domain ubiquitin 
ligase that activates the TAK1 kinase 
through polyubiquitination (reviewed 
in Chen, 2005). TAK1 in turn acti-
vates the IKK complex, which phos-834 Cell 125, June 2, 2006 ©2006 Elseviephorylates IκBs (NF-κB inhibitors) 
and targets them for ubiquitination 
and subsequent degradation. This 
releases NF-κB, which moves to 
the nucleus and regulates its target 
genes, including those that encode 
proinflammatory cytokines. It has 
been demonstrated that both TIRAP 
and MyD88 are required for activation 
of the NF-κB pathway in response to 
signaling through TLR2 and TLR4, 
whereas only MyD88 is required for 
other TLRs and the IL1R. The mecha-
nism by which TIRAP is specifically 
required for TLR2 and TLR4 signal-
ing was not understood.
In the new study, Kagan and 
Medzhitov (2006) found that TIRAP 
contains a phosphatidylinositol 
4,5-bisphosphate (PIP2) binding 
domain that targets this adaptor 
to discrete regions of the plasma 
membrane. Mutations in the PIP2 
binding domain of TIRAP—or the 
hydrolysis of cellular PIP2 by bac-
terial PIP2 phosphatases—abro-
gated the recruitment of TIRAP to 
the plasma membrane as well as 
its ability to induce cytokines in 
response to lipopolysaccharide 
(LPS, a component of the bacte-
rial cell wall). Furthermore, when 
the PIP2 binding domain of TIRAP 
was replaced with the PH domain 
of PLCδ1, which also binds to PIP2, 
the chimeric protein was capable of 
restoring TLR4 signaling in TIRAP-
deficient cells. In contrast, when r Inc.TIRAP was mislocalized to other 
membrane compartments, it failed 
to support TLR4 signaling. Interest-
ingly, when TIRAP was targeted to 
the plasma membrane through a 
PIP2-independent membrane-tar-
geting sequence (SH4 domain of 
Fyn), it could not complement TLR4 
signaling, suggesting that targeting 
of TIRAP to a specialized PIP2-con-
taining domain of the plasma mem-
brane is important for its signaling 
function. TIRAP is delivered to the 
plasma membrane from the endo-
some through a mechanism that 
depends on the ARF6 GTPase.
Why is localization of TIRAP to 
the plasma membrane important 
for TLR4 signaling? It turns out 
that the sole function of TIRAP is 
to recruit MyD88 to the plasma 
membrane (Figure 1). Both TIRAP 
and MyD88 contain TIR domains 
that allow them to interact. In cells 
containing TIRAP mutants that fail 
to localize to the PIP2-containing 
membrane, MyD88 is not recruited 
to the plasma membrane. Remark-
ably, when MyD88 was fused to the 
PIP2-targeting sequence of PLCδ1 
(which allows it to localize directly to 
the plasma membrane), this fusion 
protein completely restored LPS 
signaling in cells lacking TIRAP as 
well as those lacking both TIRAP 
and MyD88. The same fusion pro-
tein, however, failed to rescue IL-
1β signaling in cells lacking both 
TIRAP and MyD88, suggesting that 
the IL-1β receptor and TLR4 signal 
from distinct domains in the plasma 
membrane.
The obligatory requirement for 
targeting TIRAP and MyD88 to 
PIP2-containing membranes raises 
the interesting possibility that TLR 
signaling may be regulated by phos-
pholipid metabolism (Figure 1). 
Growth factors and integrin signal-
ing are known to regulate the pro-
duction of PIP2 (McLaughlin et al., 
2002). It has been shown previously 
that macrophages lacking the integ-
rin CD11b are less responsive to LPS 
(Flo et al., 2000; Perera et al., 2001), 
but the mechanism has not been 
elucidated. The study by Kagan and 
Medzhitov (2006) now provides a 
mechanism that links this integrin to 
TLR4 signaling. They demonstrated 
that the plasma-membrane local-
ization of TIRAP and LPS-induced 
production of the proinflammatory 
cytokine IL-6 were severely impaired 
in CD11b-deficient mac-
rophages, whereas the 
induction of chemokines 
through the TIRAP-inde-
pendent pathway was 
intact in the absence of 
CD11b. It will be interest-
ing to determine whether 
other signaling path-
ways that regulate PIP2 
metabolism also affect 
TLR2 and TLR4 signaling. 
If so, antagonists of PIP2 
production may be used 
to treat inflammatory dis-
eases caused by aberrant 
activation of TLRs.
The Kagan and Med-
zhitov (2006) study rep-
resents a major advance 
in the mechanistic under-
standing of TLR signaling. 
Like many other impor-
tant discoveries, the role 
of PIP2 in TLR4 signal-
ing also raises important 
questions that await fur-
ther research. One ques-
tion is whether PIP2 sim-
ply recruits TIRAP and 
subsequently MyD88 to 
the plasma membrane or 
whether this phospholipid has addi-
tional roles. Since only the PIP2 bind-
ing domain, but not another plasma-
membrane-targeting domain (e.g, 
the SH4 domain), endows the abil-
ity of TIRAP to recruit MyD88 to the 
plasma membrane, it is possible that 
PIP2 may act as an allosteric regula-
tor. Alternatively, as PIP2 is present 
in the endosomal membrane, MyD88 
may have to be recruited to the endo-
somal membrane before it can move 
together with TIRAP to the plasma 
 membrane.
Another important question is 
whether a pool of endogenous 
MyD88 is constitutively associated 
with TIRAP at the plasma membrane 
or whether the recruitment of MyD88 
to the membrane is induced by 
TLR4 signaling. As TIRAP appears 
to be localized constitutively at the 
plasma membrane and contains a 
TIR domain that can associate with 
the TIR domain of MyD88, it is pos-
sible that the pool of MyD88 that 
mediates TLR4 signaling is already in 
the vicinity of TLR4. The engagement 
of TLR4 may lead to the oligomer-
ization of the cytosolic TIR domain 
or a conformational change of this 
domain that allows the recruitment of 
MyD88. Alternatively, the recruitment 
of MyD88 to the plasma membrane 
may require both TIRAP and the 
engagement of TLR4. These possi-
bilities can be distinguished by visu-
alizing the trafficking of endogenous 
MyD88 following LPS treatment.
The regulation of adaptors through 
membrane tethering is not restricted 
to TIRAP. In fact, a recent study from 
Golenbock and colleagues (Rowe et 
al., 2006) found that the related adaptor 
TRAM contains an N-terminal myris-
toylation site that is responsible for tar-
geting TRAM to the plasma membrane, 
where it colocalizes with TLR4. Muta-
tions in the N-myristoylation sequence 
of TRAM abrogated the membrane 
localization of TRAM as well as its abil-
ity to induce cytokines in response 
to LPS. TRAM acts exclu-
sively in the TLR4 pathway 
(Fitzgerald et al., 2003; 
Yamamoto et al., 2003). In 
addition to the activation of 
NF-κB signaling via TIRAP 
and MyD88, TLR4 also acti-
vates a MyD88-indepen-
dent response resulting in 
the activation of interferon 
(IFN) regulatory factor 3 
(IRF3) and the induction 
of type-I IFNs, as well as a 
delayed NF-κB response 
(Figure 1). TRIF is critical 
for these MyD88-indepen-
dent responses. Membrane 
localization of TRAM func-
tions to recruit and activate 
TRIF, which engages the 
downstream kinase TBK1 
to activate IRF3 and induce 
IFN gene transcription. In 
contrast to TLR4 signaling, 
TLR3 recruits TRIF directly 
to engage the IRF3 and NF-
κB pathways.
The emerging theme 
from these recent studies 
is that TLR4 has evolved 
to employ the sorting 
adaptors TIRAP and 
Figure 1. The Sorting and Signaling Adaptors in TLR4 
Responses
β2 integrin signaling (e.g., CD11b) regulates PIP2 production via ARF6 
and PI5K. TIRAP/Mal contains a PIP2 binding domain, which facilitates 
its recruitment to the plasma membrane and association with TLR4. 
TLR4 and the coreceptor MD2 bind LPS, and this binding triggers the 
recruitment of TIR-domain-containing adaptors to the receptor com-
plex. TIRAP functions as a “sorting adaptor” to recruit the “signaling 
adaptor” MyD88. MyD88 engages downstream IRAK kinases and the 
TRAF6 ubiquitin ligase to propagate signals to NF-κB and AP-1 tran-
scription factors. Analogous to TIRAP, TRAM—which is localized to the 
plasma membrane through N-terminal myristoylation (Myr)—functions 
as a sorting adaptor to recruit its signaling adaptor TRIF. TRIF engages 
TANK binding kinase 1 (TBK1), leading to IRF3 activation. There is also 
crosstalk between the TRAM-TRIF and TIRAP-MyD88 pathways for 
the regulation of NF-κB and inflammatory cytokines.Cell 125, June 2, 2006 ©2006 Elsevier Inc. 835
TRAM to recruit the signaling adap-
tors MyD88 and TRIF, respectively, 
to specialized regions of the plasma 
membrane where signaling com-
plexes are assembled. TLR2 may 
use a similar combination of sort-
ing (TIRAP) and signaling (MyD88) 
adaptors to initiate signaling from 
the plasma membrane. However, for 
many other TLRs that signal solely 
through MyD88 (TLR5, 7, 8, 9, and 
11) or TRIF (TLR3), there are no 
known sorting adaptors. A future 
challenge will be to understand how 
these TLRs sort out the signals.836 Cell 125, June 2, 2006 ©2006 Elsevi
For decades, computer scientists 
have been working on the manipula-
tion and analysis of strings of data. 
Many of the techniques they have 
developed for analyzing large corpora 
of text can be easily adapted to the 
examination of megabases of DNA 
information present in the human 
genome. A new study reported by 
Rigoutsos and colleagues in a recent 
issue of PNAS reveals the insights 
gained by applying computer sci-
ence to biological problems. This 
study investigates the relationships 
between short repeated elements 
in genic and nongenic DNA in the 
human genome (Rigoutsos et al., 
2006) using a pattern discovery tool 
called TEIRESIAS (Rigoutsos and 
Floratos, 1998). TEIRESIAS is based 
on a clever computational trick that 
allows the identification of overrep-
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computation is made manageable by 
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which enforces a restricted search 
space. Other methods that also 
make use of this sparsity are based 
on suffix trees (Ettwiller et al., 2005; 
Xie et al., 2005). TEIRESIAS’s unique 
advantage is its two-stage proc-
ess of building longer patterns from 
shorter ones.
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instances were nonoverlapping. 
There were 127,998 of these patterns, 
far more than one would expect to 
appear by chance. They called these 
sequence patterns pyknons from the 
Greek word meaning “dense.” Inter-
estingly, these pyknons are found 
more often in the 3′ untranslated 
regions (UTRs) of genes than in other 
regions of the genome (7.33% nucle-
otide coverage compared to 3.04% 
in exons) (Figure 1). The spacing of 
pyknons in 3′ UTRs is also sugges-
tive, with the average inter-pyknon 
distance falling between 18 and 22 
nucleotides. Rigoutsos et al. (2006) 
suggest that this finding hints at the 
possibility of complex posttranscrip-
tional regulation events, such as 
those mediated by miRNAs. Small 
regulatory RNA sequences are typi-
man Genome
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